Skip to main content

Adage Capital Management — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$11.1B
Total invested
$160.5M
Avg. check
27
Industries
Biotechnology 21Therapeutics 12Health Care 10Pharmaceutical 9Biopharma 8Medical 5+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 76
Monopar
September 2025

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

Biopharma · Wilmette$135.0M Post-IPO Equity
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post-IPO Equity
Arvinas
August 2025

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

Biotechnology · New HavenPost-IPO Equity
CinCor Pharma
August 2022

CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.

Biotechnology · Cincinnati$225.0M Post-IPO Equity
LB Pharmaceuticals
July 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$150.0M Post-IPO Equity
Helus Pharma
June 2026

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Biotechnology · Toronto$50.0M Post-IPO Equity
Shattuck Labs
June 2026

Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.

Biopharma · Austin$75.0M Post-IPO Equity
Cabaletta Bio
May 2026

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Biotechnology · Philadelphia$150.0M Post-IPO Equity
connectRN
May 2023

ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.

Health Care · Waltham$750K Convertible Note
Werewolf Therapeutics
May 2022

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Biotechnology · Cambridge$50.0M Post-IPO Secondary
SiMa.ai
April 2026

SiMa.ai is a developer of machine learning technology to deliver a software-centric platform.

AI Infrastructure · San JoseCorporate Round
Opus Genetics(formerly Ocuphire Pharma)
April 2026

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

Biopharma · Farmington Hills$35.0M Post-IPO Debt
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Ray Therapeutics
April 2026

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

Biotechnology · San Diego$125.0M Series B
Trevi Therapeutics
April 2026

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$173.0M Post-IPO Equity
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post-IPO Equity
Spyre Therapeutics
April 2026

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$403.0M Post-IPO Equity
Menlo Micro
March 2022

Menlo Micro is the developer of the Ideal Switch, an electromechanical switch technology used to switch AC/DC and RF.

Consumer Electronics · Irvine$150.0M Series C
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post-IPO Equity
Calithera Biosciences
March 2022

Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.

Biotechnology · South San Francisco$10.0M Post-IPO Equity
Palisade Bio
March 2026

Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.

Biopharma · Carlsbad$3.0M Post-IPO Equity
MedAvail
March 2023

MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products.

Biotechnology · Mississauga$16.0M Post-IPO Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post-IPO Equity
Puma Biotechnology
March 2022

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

Biotechnology · Los Angeles$10.0M Post-IPO Equity

Where Adage Capital Management invests

Biotechnology21
Therapeutics12
Health Care10
Pharmaceutical9
Biopharma8
Medical5

About Adage Capital Management's portfolio

How many companies has Adage Capital Management invested in?

Adage Capital Management has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Adage Capital Management invest in?

Adage Capital Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Pharmaceutical, Biopharma. The firm invests across 27 different industry categories.

What is Adage Capital Management's largest investment?

Among tracked funding rounds, Spyre Therapeutics received $403.0M in a Post-IPO Equity round. Adage Capital Management's total known invested capital is $11.1B.

What is the average investment size for Adage Capital Management?

Adage Capital Management's average investment size is $160.5M across its portfolio of 76 companies.

What are Adage Capital Management's most recent investments?

Recent Adage Capital Management portfolio additions include Monopar, Ventyx Biosciences, Arvinas, CinCor Pharma, LB Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →